Conformational change propagation in ATIII-heparin

ATIII-肝素中的构象变化传播

基本信息

  • 批准号:
    7155798
  • 负责人:
  • 金额:
    $ 4.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-01-01 至 2008-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The essential anticoagulant protein antithrombin III (ATIII) uses a serpin suicide substrate mechanism to form inhibitory complexes with clotting enzymes. However, native circulating ATIII is an inefficient proteinase inhibitor due to partial insertion of its reactive loop in its central A beta-sheet. For full activation, cofactor heparin must bind ATIII and induce a protein conformational change that leads to reactive loop expulsion and about 300x increase in the fXa inhibition rate. The mechanism of ATIII activation by heparin is reasonably well understood at the first stage of cofactor binding to the inhibitor and the final stage of reactive loop expulsion. In contrast, much less is known about intermediate steps responsible for propagation of the activating conformational change from the pentasaccharide-binding site to the reactive loop. The goals of this work are to identify ATIII structural elements and interactions that mediate conformational change transmission, and to develop a better understanding of this pharmaceutically important allosteric activation mechanism. Our working model proposes that 3 prongs of conformational change radiate from the pentasaccharide-ATIII interface. Prong-1 leads to helix P (hP) formation and then converges with prong-2 (which is transmitted through the N-terminal polypeptide) to restructure the hE arm and rotate Y166. Y166 rotation promotes sheet-A closure at the equator of the inhibitor. Sheet A closure at the reactive loop pole is similarly promoted by prong-3-mediated Y131 rotation. (Prong 3 is relayed through hA, sB and hD following ATIII binding to the pentasaccharide non-reducing end.) As strands 2 and 3 of sheet-A move away from hD and hE, they pass under the hF arm which with a network of A-sheet residues directly stabilizes the inserted reactive loop and partially opened A-sheet of the native conformation. Tyrosine rotation-driven movement of s2A/s3A under the hF arm disrupts this native network and frees its components to engage in different linkages that stabilize the P14-expelled closed A-sheet activated molecule. The model for heparin dependent conformational change propagation in ATIII will be evaluated and refined by disrupting hypothesized, critical structural interactions and determining how such changes affect heparin affinity and binding kinetics, allosteric activation of fXa inhibition and the molecular structures of the mutants.
描述(由申请方提供):必需抗凝蛋白抗凝血酶III(ATIII)使用丝氨酸蛋白酶抑制剂自杀底物机制与凝血酶形成抑制复合物。然而,天然循环ATIII是一种低效的蛋白酶抑制剂,因为其反应环部分插入其中央A β折叠中。对于完全激活,辅因子肝素必须结合ATIII并诱导蛋白质构象变化,导致反应性环排出和fXa抑制率增加约300倍。在辅因子结合抑制剂的第一阶段和反应环排出的最后阶段,肝素激活ATIII的机制得到了合理的理解。相比之下,少得多的是已知的中间步骤负责传播的激活构象变化从pentasglide结合位点的反应环。这项工作的目标是确定ATIII结构元件和介导构象变化传递的相互作用,并更好地了解这种药学上重要的变构激活机制。我们的工作模型提出,3个叉的构象变化辐射从pentassistide-ATIII接口。叉-1导致螺旋P(hP)形成,然后与叉-2(其通过N-末端多肽传递)会聚以重构hE臂并旋转Y166。Y166旋转促进A片在抑制剂赤道处闭合。在反应回路极点处的片A闭合类似地由叉-3介导的Y131旋转促进。(在ATIII结合至五糖非还原末端之后,叉头3通过hA、sB和hD中继。)当A片层的链2和3远离hD和hE移动时,它们在hF臂下通过,该hF臂与A片层残基的网络一起直接稳定插入的反应性环和天然构象的部分打开的A片层。酪氨酸旋转驱动的s2 A/s3 A在hF臂下的运动破坏了这种天然网络,并释放其组分以参与不同的连接,这些连接稳定了P14排出的闭合A折叠活化分子。ATIII中肝素依赖性构象变化传播的模型将通过破坏假设的关键结构相互作用并确定此类变化如何影响肝素亲和力和结合动力学、fXa抑制的变构激活和突变体的分子结构来进行评价和完善。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUSAN C BOCK其他文献

SUSAN C BOCK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUSAN C BOCK', 18)}}的其他基金

Development of Cross Protective H5 Hemagglutinin Antigens
交叉保护性 H5 血凝素抗原的开发
  • 批准号:
    8072917
  • 财政年份:
    2010
  • 资助金额:
    $ 4.52万
  • 项目类别:
Development of Cross Protective H5 Hemagglutinin Antigens
交叉保护性 H5 血凝素抗原的开发
  • 批准号:
    7880704
  • 财政年份:
    2009
  • 资助金额:
    $ 4.52万
  • 项目类别:
Development of Cross Protective H5 Hemagglutinin Antigens
交叉保护性 H5 血凝素抗原的开发
  • 批准号:
    7741349
  • 财政年份:
    2009
  • 资助金额:
    $ 4.52万
  • 项目类别:
Conformational change propagation in ATIII-heparin
ATIII-肝素中的构象变化传播
  • 批准号:
    7331505
  • 财政年份:
    2005
  • 资助金额:
    $ 4.52万
  • 项目类别:
Conformational change propagation in ATIII-heparin
ATIII-肝素中的构象变化传播
  • 批准号:
    6869382
  • 财政年份:
    2005
  • 资助金额:
    $ 4.52万
  • 项目类别:
Antithrombin targeting to HSPG & heparin coated surfaces
针对 HSPG 的抗凝血酶
  • 批准号:
    6913869
  • 财政年份:
    2005
  • 资助金额:
    $ 4.52万
  • 项目类别:
Antithrombin targeting to HSPG & heparin coated surfaces
针对 HSPG 的抗凝血酶
  • 批准号:
    7020710
  • 财政年份:
    2005
  • 资助金额:
    $ 4.52万
  • 项目类别:
Conformational change propagation in ATIII-heparin
ATIII-肝素中的构象变化传播
  • 批准号:
    6999371
  • 财政年份:
    2005
  • 资助金额:
    $ 4.52万
  • 项目类别:
Conformational change propagation in ATIII-heparin
ATIII-肝素中的构象变化传播
  • 批准号:
    7166099
  • 财政年份:
    2005
  • 资助金额:
    $ 4.52万
  • 项目类别:
SERPIN STRUCTURE AND THE DEVELOPMENT OF NEUTROPHIL RESISTANT SERPINS
Serpin 结构和中性粒细胞抗性 Serpin 的开发
  • 批准号:
    6485295
  • 财政年份:
    2001
  • 资助金额:
    $ 4.52万
  • 项目类别:

相似海外基金

Antithrombin III attenuates the formation of neutrophil extracellular traps during sepsis
抗凝血酶 III 减弱脓毒症期间中性粒细胞胞外陷阱的形成
  • 批准号:
    16K11403
  • 财政年份:
    2016
  • 资助金额:
    $ 4.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
METHODS FOR DETERMINATION OF HS EPITOPES THAT BIND ANTITHROMBIN III
测定结合抗凝血酶 III 的 HS 表位的方法
  • 批准号:
    7955915
  • 财政年份:
    2009
  • 资助金额:
    $ 4.52万
  • 项目类别:
METHODS FOR DETERMINATION OF HS EPITOPES THAT BIND ANTITHROMBIN III
测定结合抗凝血酶 III 的 HS 表位的方法
  • 批准号:
    7722999
  • 财政年份:
    2008
  • 资助金额:
    $ 4.52万
  • 项目类别:
METHODS FOR DETERMINATION OF HS EPITOPES THAT BIND ANTITHROMBIN III
测定结合抗凝血酶 III 的 HS 表位的方法
  • 批准号:
    7601993
  • 财政年份:
    2007
  • 资助金额:
    $ 4.52万
  • 项目类别:
METHODS FOR DETERMINATION OF HS EPITOPES THAT BIND ANTITHROMBIN III
测定结合抗凝血酶 III 的 HS 表位的方法
  • 批准号:
    7369255
  • 财政年份:
    2006
  • 资助金额:
    $ 4.52万
  • 项目类别:
Analysis of syndecan-4 core protein as a receptor for antithrombin III
Syndecan-4 核心蛋白作为抗凝血酶 III 受体的分析
  • 批准号:
    18390479
  • 财政年份:
    2006
  • 资助金额:
    $ 4.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
METHODS FOR DETERMINATION OF HS EPITOPES THAT BIND ANTITHROMBIN III
测定结合抗凝血酶 III 的 HS 表位的方法
  • 批准号:
    7182210
  • 财政年份:
    2005
  • 资助金额:
    $ 4.52万
  • 项目类别:
The new type of receptor for antithrombin III that has anti-inflammatory effect
具有抗炎作用的新型抗凝血酶III受体
  • 批准号:
    16390513
  • 财政年份:
    2004
  • 资助金额:
    $ 4.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Increase in antithrombotic function vascular endothelium antithrombin-III
抗血栓功能增加血管内皮抗凝血酶-III
  • 批准号:
    11838017
  • 财政年份:
    1999
  • 资助金额:
    $ 4.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular pathology of novel two variants of antithrombin III
抗凝血酶 III 的两种新型变体的分子病理学
  • 批准号:
    04671529
  • 财政年份:
    1992
  • 资助金额:
    $ 4.52万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了